TCGA-AR-A0TR-01A-11R-A084-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 5
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.330
- PROTEIN_SECRETION+0.300
- MYC_TARGETS_V2+0.270
- DNA_REPAIR+0.190
- ESTROGEN_RESPONSE_EARLY+0.140
- HEME_METABOLISM+0.110
- MYC_TARGETS_V1+0.110
- OXIDATIVE_PHOSPHORYLATION+0.110
- PI3K_AKT_MTOR_SIGNALING+0.110
- MITOTIC_SPINDLE+0.030
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.670
- ANGIOGENESIS-0.600
- TNFA_SIGNALING_VIA_NFKB-0.530
- INFLAMMATORY_RESPONSE-0.490
- KRAS_SIGNALING_UP-0.480
- ALLOGRAFT_REJECTION-0.460
- INTERFERON_GAMMA_RESPONSE-0.460
- COAGULATION-0.450
- APICAL_JUNCTION-0.430
- APICAL_SURFACE-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617882 | — | B | 0.919 |
| 2 | SRR1348446 | GTEX | — | 0.908 |
| 3 | SRR655864 | GTEX | — | 0.903 |
| 4 | TCGA-A8-A08C-01A-11R-A00Z-07 | — | B | 0.902 |
| 5 | MBCProject_0343_T1_RNA | — | B | 0.899 |
| 6 | SRR1410934 | GTEX | — | 0.899 |
| 7 | SRR819999 | GTEX | — | 0.897 |
| 8 | SRR1451897 | GTEX | — | 0.895 |
| 9 | SRR1500537 | GTEX | — | 0.893 |
| 10 | SRR1322270 | GTEX | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |